Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (noted as Harrow, Inc. in metadata) on December 29, 2016, reporting events occurring on December 27, 2016. The filing details a material amendment to the company's existing debt facilities and related equity instruments with IMMY Funding LLC.
Key Financial Metrics and Debt Structure
- Total Outstanding Principal: The aggregate outstanding principal balance due to the Lender, including interest paid in kind, is $13,332,255.
- Debt Restructuring: A $3,000,000 convertible note was exchanged for a $3,000,000 term loan (Term B Loan). No new cash funding was provided for this exchange.
- Equity Instrument: A warrant to purchase up to 125,000 shares of Common Stock was amended to reduce the exercise price to $1.79.
- Collateral: The debt is secured by a security interest in substantially all personal property, rights, and assets of the Company and its subsidiaries, including intellectual property.
Material Changes Versus Prior Period
The primary material change is the conversion of a convertible note into a term loan structure, altering the repayment mechanics while maintaining the principal amount. Additionally, the reduction of the warrant exercise price represents a significant modification to the terms of the equity kicker previously granted to the lender.
Management Commentary, Risks, and Covenants
The filing outlines strict negative covenants that restrict the Company's operations while the debt is outstanding. Key restrictions include:
- Prohibitions on disposing of business or property.
- Restrictions on incurring additional indebtedness.
- Bans on mergers, acquisitions, or change of control transactions without consent.
- Prohibitions on paying dividends or repurchasing capital stock.
- Restrictions on incurring new liens on assets.
Events of Default: The agreement defines events of default that could trigger immediate repayment of all amounts owed. These include bankruptcy, failure to make payments, material adverse changes in business operations, breach of material agreements, regulatory enforcement actions, or significant fines/judgments.
Investor Verification Checklist
- Verify the full text of the Third Amendment to the Loan and Security Agreement (Exhibit 10.1) for specific amortization schedules and interest rates.
- Confirm the current cash position of the Company to assess its ability to meet the $13.3 million aggregate obligation under the new terms.
- Review the impact of the reduced warrant exercise price ($1.79) on potential future dilution.
- Assess the Company's compliance with the newly defined negative covenants regarding future financing or asset sales.